Share Fillip As Indian Pharma Crests US Regulatory Hump
This article was originally published in PharmAsia News
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
You may also be interested in...
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.
Sun Pharma, the world’s fifth-largest generics maker, has become the latest in a string of Indian drug companies to ramp up its interest in the OTC sector as it seeks to buffer its revenue stream from regulatory uncertainties and currency volatility.